Valeant Pharmaceuticals International, Inc. provided earnings guidance for fiscal 2013. For the period, the company expects revenue between $4.4 billion - $4.8 billion, cash EPS between $5.45 -$5.75 and adjusted cash flow from
operations between $1.5 billion - $1.75 billion.